PMA device
PD-L1 IHC 28-8 pharmDx
Agilent Technologies, Inc. · Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS, Class III) · First FDA decision May 3, 2017, newest Jul 1, 2026Cancer detection and genomic testingLung cancer and lung nodules
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
0
Naming "PD-L1 IHC 28-8"
MAUDE reports
1
Brand "PD-L1 IHC 28-8", since 2015
PubMed studies
15
Mentioning "PD-L1 IHC 28-8"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PD-L1 IHC 28-8 pharmDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S014 · Decided Oct 18, 2021 · 98 days after receipt · Normal 180 Day Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S013 · Decided May 15, 2020 · 151 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PD-L1 IHC 28-8", any status and sponsor, newest update first.
No registered device study names "PD-L1 IHC 28-8".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PD-L1 IHC 28-8", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code PLS
35 reports: 34 malfunction, 1 injury, 0 death
Newest reports for this brand
- PD-L1 IHC 28-8 PHARMDXMalfunction
2916205-2020-00001 · Received Dec 22, 2020 · Event dated Nov 24, 2020
Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PD-L1 IHC 28-8"[tiab]. The summary above synthesizes these.
- Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
Krigsfeld GS, Prince EA, Pratt J, et al. · J Clin Pathol · 2020
- Programmed death-ligand 1 expression in gastric cancer by the combined positive score using the PD-L1 IHC 28-8 pharmDx test: a single institution's experience.
Hamaguchi T, Furusawa K, Watanabe M, et al. · Jpn J Clin Oncol · 2026
- A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C, Albitar M, Zerba K, et al. · J Clin Pathol · 2018
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT · Expert Rev Mol Diagn · 2016Editorial
- Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
Novotny JF, Cogswell J, Inzunza H, et al. · Ann Oncol · 2016Editorial, Research Support, Non-U.S. Gov't
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R, Gosney JR, Skov BG, et al. · J Clin Oncol · 2017Review
- Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Zajac M, Scott M, Ratcliffe M, et al. · Diagn Pathol · 2019
- Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG · Appl Immunohistochem Mol Morphol · 2021Research Support, Non-U.S. Gov't, Validation Study
- An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT · Expert Rev Mol Diagn · 2021Review
- Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.
Lawson NL, Dix CI, Scorer PW, et al. · Mod Pathol · 2020Research Support, Non-U.S. Gov't
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D, Suzman DL, Blumenthal G, et al. · Oncologist · 2016Multicenter Study, Randomized Controlled Trial
- Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Koppel C, Schwellenbach H, Zielinski D, et al. · Mod Pathol · 2018Validation Study
Other devices of this type
Also filed under product code PLS.
- PD-L1 IHC 22C3 pharmDxAgilent Technologies, Inc. · PMA 2026
- VENTANA PD-L1 (SP263) AssayVentana Medical Systems, Inc. · PMA 2023
- VENTANA PD-L1 (SP263) CDx AssayVentana Medical Systems, Inc. · PMA 2024
- PD-L1 Ihc 28-8 PharmdxDako North America, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.